Michael Landsittel - May 2, 2024 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Signature
/s/ Melissa Masse, Attorney-in-Fact
Stock symbol
BPMC
Transactions as of
May 2, 2024
Transactions value $
-$689,500
Form type
4
Date filed
5/6/2024, 05:26 PM
Previous filing
Apr 1, 2024
Next filing
May 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Options Exercise $361K +10K +21.15% $36.05 57.3K May 2, 2024 Direct F1
transaction BPMC Common Stock Sale -$1.05M -10K -17.46% $105.00 47.3K May 2, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Options Exercise $0 -10K -100% $0.00* 0 May 2, 2024 Common Stock 10K $36.05 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Effected through a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 This option was granted on February 16, 2017 and is fully vested as of the transaction date.